Beta Blockers in MI: Old Drug, New Lens, Possible Win 🔍💥🏥

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there's no heart failure? 🤔   In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉   📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p=0.03 💡 Especially lowered risk of recurrent MI (HR 0.73)   🧠 Even in the era of PCI, DAPT & statins, beta-blockers may still bring benefit — especially in patients with mildly reduced LVEF (40–49%) 🫀   🔗 [Add your slide link or DOI here] #Cardiology #NEJM #HeartAttack #BetaBlockers #PostMI #EvidenceBasedMedicine #LVEF #PrecisionMedicine #ClinicalTrials